RD
Rob De Ree
Chair valorisation DCVA at Dutch CardioVascular Alliance
Amsterdam, North Holland
Overview
Rob de Ree is the CEO of NorthSea Therapeutics B.V., with a background in cardiology and extensive experience in market development and product launch. Notable highlights include serving as CEO of Dezima Pharma and Vice President at Edwards Lifesciences, showcasing a successful track record in leadership roles within the pharmaceutical and medical industry.
Work Experience
Chair valorisation DCVA
2018 - Current
CEO
2017
Operating Partner
2016
Member of the Supervisory Board
2014 - 2024
Chairman of the Supervisory Board
2015 - 2017
general manager Dezima Pharma
2015 - 2016
Dezima Pharma has been acquired by Amgen
Amgen is a biotechnology company that develops and manufactures human therapeutics for various illnesses and diseases.
Raised $28,500,000,000.00 from Citibank and Bank of America.
CEO
2013 - 2015
Dezima Pharma develops innovative drugs in the field of dyslipidemia.
Vice President Critical Care non-invasive
2012 - 2013
BMEYE BV has been acquired by Edwards Lifesciences
Edwards Lifesciences is a provider of science of heart valves and hemodynamic monitoring.
CEO
2008 - 2012
VP sales & marketing
2007 - 2008
Sr. Director Business Development
2006 - 2007
Education
Master's degree
1983 - 1991